Skip to main content
Fresenius SE & Co. KGaA logo

Fresenius SE & Co. KGaA — Investor Relations & Filings

Ticker · FRE ISIN · DE0005785604 LEI · XDFJ0CYCOO1FXRFTQS51 F Human health and social work activities
Open in API
Filings indexed 1,398 across all filing types
Latest filing 2020-11-02 Director's Dealing
Country DE Germany
Listing F FRE

About Fresenius SE & Co. KGaA

https://www.fresenius.com/

Fresenius SE & Co. KGaA is a global healthcare company that provides system-critical products and services for leading therapies for the care of critically and chronically ill patients. The company's portfolio encompasses a wide range of products and services for dialysis, hospitals, and outpatient medical care. Key offerings include intravenously administered generic drugs, biopharmaceuticals, biosimilars, clinical nutrition, and infusion therapies. Additionally, the company operates a large network of private hospitals and outpatient centers. Through its strategic investment in Fresenius Medical Care, it is a leading global provider of products and services for individuals with renal diseases.

Recent filings

Filing Released Lang Actions
DGAP-DD: Fresenius SE & Co. KGaA english
Director's Dealing Classification · 100% confidence The document is explicitly titled 'Directors’ Dealings' and contains detailed information regarding a transaction (Acquisition) by a 'person discharging managerial responsibilities' (Dr. Gerd Krick, Member of the administrative or supervisory body) in the issuer's shares. This directly matches the definition for Director's Dealing (DIRS). The structure follows standard regulatory disclosure formats for insider transactions.
2020-11-02 English
Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'Total Voting Rights Announcement' and explicitly mentions the 'Publication of total number of voting rights' and details a 'Type of capital measure' (Conditional capital increase). This content directly relates to changes in the company's capital structure or voting rights, which aligns best with the 'Capital/Financing Update' (CAP) category, as it announces a change affecting the total number of shares/votes. While it is a regulatory announcement (WpHG), the specific nature of the announcement points more precisely to CAP than the general 'RNS' fallback. It is not a full report, but a specific notification about capital structure.
2020-10-30 English
Conference Call Q3 Results 2020, Fresenius
Investor Presentation Classification · 99% confidence The document is explicitly titled "Conference Call – Q3/20 Results" and contains key messages, segment performance breakdowns (Fresenius Kabi, Helios Germany, Helios Spain, Fresenius Vamed), financial tables for Q3/20, and guidance for FY/20. This structure is characteristic of materials presented during an earnings conference call, which includes management discussion and Q&A (though the Q&A transcript itself is not present, the presentation slides/summary are). This aligns perfectly with the definition of a Call Transcript (CT), as it is the content derived from or used in such a call. It is not a formal regulatory filing like a 10-K or an Earnings Release (ER) which is usually a very brief press release announcing the numbers; this is a detailed presentation.
2020-10-29 English
Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'Total Voting Rights Announcement' and explicitly mentions the 'Publication of total number of voting rights' as of '30.09.2020'. It details a 'Type of capital measure' related to a 'Conditional capital increase' and states the 'New total number of voting rights'. This content directly relates to changes in the company's capital structure and the resulting voting power, which aligns best with the 'Share Issue/Capital Change' category (SHA). Although it is a regulatory announcement (DGAP), the specific subject matter is capital structure change, making SHA more precise than the general RNS fallback.
2020-09-30 English
Berenberg & Goldman Sachs – 9th German Corporate Conference (Virtual)
Investor Presentation Classification · 99% confidence The document is titled 'Berenberg & Goldman Sachs 9th German Corporate Conference' and contains extensive slides detailing the company's business segments (Fresenius Medical Care, Kabi, Helios, Vamed), market dynamics, growth drivers, medium-term targets (2020-2023), ESG overview, capital deployment, dividend policy, and a review of Q2/20 performance amid the COVID-19 pandemic. This structure—a presentation deck summarizing strategy, performance, and outlook—is characteristic of an Investor Presentation (IP). It is not a formal regulatory filing like a 10-K or IR, nor is it a short announcement (RPA/RNS).
2020-09-22 English
Baader Investment Conference 2020 (Virtual)
Investor Presentation Classification · 100% confidence The document is titled "Baader Investment Conference 2020" and is dated September 21, 2020. It contains extensive slides detailing the company's business segments (Fresenius Medical Care, Kabi, Helios, Vamed), global trends, medium-term growth targets, ESG priorities, capital deployment, and a review of Q2/20 performance in the context of the COVID-19 pandemic. This structure—a presentation given at an investment conference, covering strategy, performance review, and outlook—is characteristic of an Investor Presentation (IP). It is not a formal regulatory filing like a 10-K or an ER, nor is it a transcript of a call (CT).
2020-09-21 English

Browse filings by year

31 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.